Spain

PHARMA MAR SA

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

SPAIN Spain

Post An Enquiry

Virtual Booth

CPhI Japan 2021

Participation Not Confirmed

Update your events

UK Approves the Start of the Phase III NEPTUNO Trial with PharmaMar's Aplidin® (Plitidepsin) for the Treatment of Patients with COVID-19

Lead Product(s): Plitidepsin

Therapeutic Area: Infections and Infectious Diseases Product Name: Aplidin

Highest Development Status: Preclinical Product Type: Peptide

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable February 17, 2021

Details:

Pharma Mar has obtained MHRA approval for UK patients to participate in the Phase III NEPTUNO clinical trial, which will determine the efficacy of Aplidin® for the treatment of hospitalized patients with moderate COVID-19 infection.

SOM Biotech

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

SPAIN Spain

Post An Enquiry

Virtual Booth

CPhI Japan 2021

Participation Not Confirmed

Update your events

SOM Biotech Announces Poster Presentation on the Repurposing of Eravacycline for the Treatment of SARS-CoV-2

Lead Product(s): Eravacycline

Therapeutic Area: Infections and Infectious Diseases Product Name: TP-434

Highest Development Status: Preclinical Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable October 19, 2020

Details:

In vitro experiments confirmed inhibition of the protease with an IC50 in the low micromolar range. Eravacycline inhibits the infection of SARS-CoV-2 in VeroE6 cells and shows no toxicity when applied alone.